Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 240

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 240
---
 of cash.

For the nine months ended September 30, 2025, net cash proceeds from operating activities were approximately
$21.3 million, attributable to the changes in operating assets and liabilities that provided $98.3 million of cash and other non-cash reconciling items of $250.9 million related to transaction costs expensed related to Semnur Business
Combination, stock-based compensation, change in fair value of debt and liability instruments, change in fair value of equity investments, change in fair value of digital assets and equity investments, financing costs, depreciation and amortization
and non-cash operating lease cost and change on fair value of derivative liabilities, partially offset by our net loss of $327.9 million.

For the nine months ended September 30, 2024, net cash proceeds from operating activities were approximately $16.8 million, attributable to
the changes in operating assets and liabilities that provided $54.9 million of cash and other non-cash reconciling items of $28.3 million related to stock-based compensation, change in fair value of debt and liability instruments, allocated
expense for warrant issuance cost, depreciation and amortization and non-cash operating lease cost, gain on derivative liabilities, partially offset by our net loss of $66.3 million.

Cash Flows from Investing Activities

For the year ended December 31, 2024, net cash used for investing activities was approximately $2.7 million and was related to
$0.6 million payments of deferred consideration for Romeg intangible asset acquisition under the Romeg License Agreement, $2.0 million purchase of the Class B ordinary shares of Denali and $0.1 million purchase of a convertible
promissory note from Denali (see Note 5 titled “Balance Sheet Components” to our consolidated financial statements included elsewhere in this prospectus for additional information).

For the year ended December 31, 2023, net cash used for investing activities was approximately $0.3 million, related to payments of
deferred consideration for Romeg intangible asset acquisition and $30.0 thousand attributed to cash paid for property and equipment purchases.

For the nine months ended September 30, 2025, net cash used for investing activities was approximately $0.7 million and was related to the
$0.2 million purchase of Gloperba Ex-U.S. rights, in-process research and development assets and $0.5 million related to payments of deferred consideration for the Romeg intangible asset